About Baxter International
Baxter International, headquartered in Deerfield, Illinois, develops products for renal care, hospital and surgical care, and pharmaceutical delivery including IV solutions and infusion systems.
Milestones
Milestones as listed on baxter.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.
Leadership Team
Leadership as listed on baxter.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.
Cynthia (Cindy) Carlisle
Products & Services
Products and services as listed on baxter.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.
Infusion Therapies and Technologies
Infusion therapy and clinical nutrition solutions.
Source: baxter.comPharmaceuticals
Injectable medicines portfolio supporting hospital pharmacy operations.
Source: baxter.comBeds and Patient Mobility
Beds and mobility equipment for patient safety and clinician efficiency.
Source: baxter.comCare Communications
Care coordination and hospital workflow technologies.
Source: baxter.comDiagnostics and Examination
Tools for patient assessment and monitoring.
Source: baxter.comRespiratory Therapy and Devices
Respiratory care devices for hospital and home.
Source: baxter.comSurgical Equipment and Technologies
Surgical products for operating room teams.
Source: baxter.comPipeline & Regulatory Record
What public registers list for Baxter International: clinical trials it sponsors, FDA device clearances, Irish licences, recent approvals and supply shortages. Rebuilt daily, last on 6 Oct 2026.
Clinical trials 1 in our ClinicalTrials.gov registers
| Study | Phase | Status |
|---|---|---|
| Evaluation of the Effectiveness of The Volara System Determined by Sputum Movement and Production NCT06937216 · Bronchiectasis Adult, COPD |
Not applicable | Not yet open |
Recent approvals
- Daptomycin In 0.9% Sodium ChlorideFDA · Daptomycin · 25 Jan 2022 · New Drug (NDA)
- Bactocill In Plastic ContainerFDA · Oxacillin Sodium · 26 Oct 1989 · New Drug (NDA)
Medicine shortages 14 in the FDA list · 17 German notices
- Amino Acid InjectionUS (FDA) · in shortage · updated 1 Oct 2026
- Dextrose Monohydrate 70% InjectionUS (FDA) · in shortage · updated 1 Oct 2026
- Dextrose Monohydrate 5% InjectionUS (FDA) · in shortage · updated 1 Oct 2026
- Dextrose Monohydrate 10% InjectionUS (FDA) · in shortage · updated 1 Oct 2026
- Sterile Water IrrigantUS (FDA) · in shortage · updated 1 Oct 2026
- Furosemide InjectionUS (FDA) · in shortage · updated 22 Sep 2026
- Ketorolac Tromethamine InjectionUS (FDA) · in shortage · updated 22 Sep 2026
- Heparin Sodium InjectionUS (FDA) · in shortage · updated 22 Sep 2026
- IxotenGermany (BfArM) · 3 Sep 2026 to 20 Nov 2026
- Uromitexan MultidoseGermany (BfArM) · 1 Jul 2026 to 31 Oct 2026
- Brevibloc 10 mg/ml InfusionslösungGermany (BfArM) · 1 May 2027 to 31 Dec 2027
- Endoxan 200 mgGermany (BfArM) · 21 Jan 2026 to 31 Dec 2026
- Endoxan 200 mgGermany (BfArM) · 21 Jan 2026 to 31 Dec 2026
A company is listed here when it is named on the shortage record; a shortage can have several manufacturers. See the US and German shortage trackers.
Group (Baxter International): founded 1931, headquarters Deerfield, website baxter.com. Wikidata Q761965 · Wikipedia. From Wikidata (CC0), matched by the group's SEC filer number.
How this is matched: register records are linked to this page by the organisation name they carry, here Baxter Healthcare Corporation; Baxter Holding B.V.; Baxter Vaccine AG; Baxter AG; Baxter Innovations GmbH; BAXTER HLTHCARE CORP and 3 more. Spot a wrong match? Tell us.
Financials & Irish Entities
From the annual reports Baxter International Inc. files with the US Securities and Exchange Commission (10-K, US GAAP), in USD as reported. Latest financial year: to Dec 2025.
| Year to | Revenue | R&D | R&D % | Net income | Filing |
|---|---|---|---|---|---|
| Dec 2025 | $11.24bn | $518m | 4.6% | −$957m | 10-K 2026 |
| Dec 2024 | $10.64bn | $590m | 5.5% | −$649m | 10-K 2026 |
| Dec 2023 | $10.36bn | $518m | 5.0% | $2.66bn | 10-K 2026 |
| Dec 2022 | $10.06bn | $450m | 4.5% | −$2.43bn | 10-K 2025 |
| Dec 2021 | $12.15bn | $531m | 4.4% | $1.28bn | 10-K 2024 |
Each year is taken from the most recent annual report that includes it, so earlier years reflect any later restatement. Source: SEC EDGAR (XBRL financial data). Compare companies on the pharma company financials register.
Companies registered in Ireland 6 active in the CRO register
| Company | CRO no. | Registered | Last accounts |
|---|---|---|---|
| Baxter Healthcare S.A. External company | 901575 | 1971 | — |
| Baxter Healthcare Limited External company | 902075 | 1979 | — |
| Baxter Shared Services & Competencies Limited LTD - Private Company Limited by Shares | 320507 | 2000 | Dec 2024 |
| Baxter Healthcare SA External company | 904362 | 2000 | — |
| Baxter Healthcare SA External company | 906483 | 2000 | — |
| Baxter Healthcare Operations Unlimited Company ULC - Private Unlimited Company | 776261 | 2024 | — |
From the Companies Registration Office (CRO Open Data, CC BY 4.0). A company is listed when GLEIF's legal entity register links it to Baxter International Inc. as its ultimate parent, or when we checked its name and registered address by hand. Branches of foreign companies appear as "External company". Spot a missing or wrong entry? Tell us.